0G99 Oxurion Nv

Leuven, BELGIUM, Boston, MA, US – October 18, 2022 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in two upcoming investor conferences.

Investival Showcase – London, UKDate: Monday, November 14, 2022 Tom Graney, CEO will be delivering a presentation and both he and Michael Dillen, CBO, will be available for one-on-one meetings. 

BTIG Ophthalmology Day – VirtualDate: Tuesday, November 29, 2022  Tom Graney, CEO, will be delivering a presentation and will be available for one-on-one meetings. 

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For further information please contact:

Attachment

• OXUR November Conferences 2022.1118

Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024